New book by Larry Connors Click here Improve your trading - See how
"Sales associated with TNF-alpha inhibitors make these agents an attractive target for biosimilar manufacturers, while the cost of TNF-alpha inhibitor therapy makes this drug class a priority for payers looking to reduce spend," stated MaryEllen Klusacek, Ph.D., analyst at Decision Resources. "We expect rheumatoid arthritis, the largest indication fueling the growth of the TNF-alpha inhibitor market, will be the first indication targeted by biosimilar developers." The new special report entitled Biosimilars: TNF-Alpha Inhibitors and Interferon-Alphas in Immune and Infectious Disease also finds that gastroenterologists and rheumatologists have a conservative attitude towards biosimilar use compared with physicians in other specialties (e.g., oncologists). Survey results suggest that physician discomfort with biosimilar TNF-alpha inhibitors and interferon-alphas (i.e., Schering-Plough's Peg Intron and Roche's Pegasys) will not prevent them from prescribing these agents. The majority of surveyed gastroenterologists and rheumatologists will be motivated to prescribe biosimilars in response to pressure from payers looking to control costs. "For the second year in a row, surveyed U.S. payers rank TNF-alpha inhibitors as their top priority for reducing biologics spend. Based on this finding, we anticipate that payer pressure on physicians to prescribe biosimilar TNF-alpha inhibitors will be high," added Dr. Klusacek. About the Report In 2009, Decision Resources expands the scope and analysis of its biosimilars product line to include oncology, immune and infectious disease and endocrinology/nephrology in three separate reports. The new report series covers 22 key biologic brands from eight biologic classes and includes surveys of 456 U.S. and European physicians and 41 managed care organization pharmacy and medical directors. About Decision Resources Decision Resources (www.decisionresources.com) is a world leader in market research publications, advisory services and consulting designed to help clients shape strategy, allocate resources and master their chosen markets. Decision Resources is a Decision Resources, Inc. company. About Decision Resources, Inc. Decision Resources, Inc. is a cohesive portfolio of companies that offers best-in-class, high-value information and insights on important sectors of the healthcare industry. Clients rely on this analysis and data to make informed decisions. Please visit Decision Resources, Inc. at www.DecisionResourcesInc.com. All company, brand or product names contained in this document may be trademarks or registered trademarks of their respective holders.
For more information, contact:
Decision Resources Decision Resources, Inc.
Gisselle Morales Elizabeth Marshall
781-296-2691 781-296-2563
gmorales@dresources.com emarshall@dresources.com
SOURCE Decision Resources http://www.decisionresources.com For full details on Amgen Inc (AMGN) click here. Amgen Inc (AMGN) has Short Term PowerRatings of 6. Details on Amgen Inc (AMGN) Short Term PowerRatings is available at This Link.
Email Print Archives Feedback Email Article Link
Close X
Related News [AMGN]
UPCOMING EVENTS
Learn new strategies, how to trade in this market, and the stocks you should be focusing on each day. Join us for our free 20 minute tele-seminars during the week.
Thursday December 3 12:30 PM
* Attendance is strictly limited and are filled on a first-come, first-served basis.
The TradingMarkets Directory
Stocks
Options
Forex
E-mini/Futures
How to Trade
Tools
PowerRatings
Blogs
Premium Subscription Services
RELATED SITES
Please call 1-213-955-5858 ext. 1
About TradingMarkets | Contact | Advertise | Careers | Link to Us | Site Map | Help | Terms & Conditions | Privacy Policy | Return Policy | Testimonials | Feedback The Connors Group, Inc. ("Company") is not an investment advisory service, nor a registered investment advisor or broker-dealer and does not purport to tell or suggest which securities or currencies customers should buy or sell for themselves. The analysts and employees or affiliates of Company may hold positions in the stocks, currencies or industries discussed here. You understand and acknowledge that there is a very high degree of risk involved in trading securities and/or currencies. The Company, the authors, the publisher, and all affiliates of Company assume no responsibility or liability for your trading and investment results. Factual statements on the Company's website, or in its publications, are made as of the date stated and are subject to change without notice. It should not be assumed that the methods, techniques, or indicators presented in these products will be profitable or that they will not result in losses. Past results of any individual trader or trading system published by Company are not indicative of future returns by that trader or system, and are not indicative of future returns which be realized by you. In addition, the indicators, strategies, columns, articles and all other features of Company's products (collectively, the "Information") are provided for informational and educational purposes only and should not be construed as investment advice. Examples presented on Company's website are for educational purposes only. Such set-ups are not solicitations of any order to buy or sell. Accordingly, you should not rely solely on the Information in making any investment. Rather, you should use the Information only as a starting point for doing additional independent research in order to allow you to form your own opinion regarding investments. You should always check with your licensed financial advisor and tax advisor to determine the suitability of any investment. HYPOTHETICAL OR SIMULATED PERFORMANCE RESULTS HAVE CERTAIN INHERENT LIMITATIONS. UNLIKE AN ACTUAL PERFORMANCE RECORD, SIMULATED RESULTS DO NOT REPRESENT ACTUAL TRADING AND MAY NOT BE IMPACTED BY BROKERAGE AND OTHER SLIPPAGE FEES. ALSO, SINCE THE TRADES HAVE NOT ACTUALLY BEEN EXECUTED, THE RESULTS MAY HAVE UNDER- OR OVER-COMPENSATED FOR THE IMPACT, IF ANY, OF CERTAIN MARKET FACTORS, SUCH AS LACK OF LIQUIDITY. SIMULATED TRADING PROGRAMS IN GENERAL ARE ALSO SUBJECT TO THE FACT THAT THEY ARE DESIGNED WITH THE BENEFIT OF HINDSIGHT. NO REPRESENTATION IS BEING MADE THAT ANY ACCOUNT WILL OR IS LIKELY TO ACHIEVE PROFITS OR LOSSES SIMILAR TO THOSE SHOWN. The Connors Group, Inc. © Copyright 2009 The Connors Group, Inc. All analyst commentary provided on TradingMarkets.com is provided for educational purposes only. The analysts and employees or affiliates of TradingMarkets.com may hold positions in the stocks or industries discussed here. This information is NOT a recommendation or solicitation to buy or sell any securities. Your use of this and all information contained on TradingMarkets.com is governed by the Terms and Conditions of Use. Please click the link to view those terms. Follow this link to read our Editorial Policy. © 2009 The Connors Group, Inc.
|
